Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study

Hitoshi Kawazoe, Ryuji Uozumi, Akari Murakami, Michiko Yamashita, Kana Kobayashi-Taguchi, Erina Kusakabe, Haruna Yamasawa, Yoshihiro Yakushijin, Tomonori Nakamura, Yoshiaki Kamei

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study aimed to compare the antiemetic efficacy and safety of a four-drug combination with those of a standard three-drug combination in Japanese patients with breast cancer treated with anthracycline. We retrospectively analyzed data from Japanese patients with breast cancer, who had received their first cycle of anthracycline and were treated with aprepitant, palonosetron, and dexamethasone with or without olanzapine. This retrospective observational study was performed at Ehime University Hospital using the electronic medical records. Multivariable and propensity score-adjusted analyses were performed to compare the onset of complete response (CR) failure between the groups. One-hundred and thirty patients were included in this study and the four- and three-drug group had 22 and 108 patients, respectively. Similar to multivariable logistic regression analysis, propensity-adjusted logistic regression analysis revealed that the four-drug group was markedly associated with a decreased odds of CR failure in the overall, acute, and delayed phases (odds ratio [OR]: 0.27, 95% confidence interval [CI]: 0.10–0.73; OR: 0.28, 95% CI: 0.10–0.76; and OR: 0.15, 95% CI: 0.04–0.57, respectively). Additionally, treatment-related adverse events were well tolerated in both the groups. These findings suggest that the antiemetic efficacy of the four-drug combination is superior to that of the standard three-drug combination.

Original languageEnglish
Article number16232
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

aprepitant
olanzapine
Anthracyclines
Drug Combinations
Nausea
Dexamethasone
Vomiting
Retrospective Studies
Breast Neoplasms
Antiemetics
Odds Ratio
Confidence Intervals
Logistic Models
Regression Analysis
Pharmaceutical Preparations
Propensity Score
Electronic Health Records
Observational Studies
Safety
palonosetron

ASJC Scopus subject areas

  • General

Cite this

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline : A retrospective study. / Kawazoe, Hitoshi; Uozumi, Ryuji; Murakami, Akari; Yamashita, Michiko; Kobayashi-Taguchi, Kana; Kusakabe, Erina; Yamasawa, Haruna; Yakushijin, Yoshihiro; Nakamura, Tomonori; Kamei, Yoshiaki.

In: Scientific Reports, Vol. 8, No. 1, 16232, 01.12.2018.

Research output: Contribution to journalArticle

Kawazoe, Hitoshi ; Uozumi, Ryuji ; Murakami, Akari ; Yamashita, Michiko ; Kobayashi-Taguchi, Kana ; Kusakabe, Erina ; Yamasawa, Haruna ; Yakushijin, Yoshihiro ; Nakamura, Tomonori ; Kamei, Yoshiaki. / Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline : A retrospective study. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{370c8ab269ed487e8c8dd0e47c89700a,
title = "Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study",
abstract = "This study aimed to compare the antiemetic efficacy and safety of a four-drug combination with those of a standard three-drug combination in Japanese patients with breast cancer treated with anthracycline. We retrospectively analyzed data from Japanese patients with breast cancer, who had received their first cycle of anthracycline and were treated with aprepitant, palonosetron, and dexamethasone with or without olanzapine. This retrospective observational study was performed at Ehime University Hospital using the electronic medical records. Multivariable and propensity score-adjusted analyses were performed to compare the onset of complete response (CR) failure between the groups. One-hundred and thirty patients were included in this study and the four- and three-drug group had 22 and 108 patients, respectively. Similar to multivariable logistic regression analysis, propensity-adjusted logistic regression analysis revealed that the four-drug group was markedly associated with a decreased odds of CR failure in the overall, acute, and delayed phases (odds ratio [OR]: 0.27, 95{\%} confidence interval [CI]: 0.10–0.73; OR: 0.28, 95{\%} CI: 0.10–0.76; and OR: 0.15, 95{\%} CI: 0.04–0.57, respectively). Additionally, treatment-related adverse events were well tolerated in both the groups. These findings suggest that the antiemetic efficacy of the four-drug combination is superior to that of the standard three-drug combination.",
author = "Hitoshi Kawazoe and Ryuji Uozumi and Akari Murakami and Michiko Yamashita and Kana Kobayashi-Taguchi and Erina Kusakabe and Haruna Yamasawa and Yoshihiro Yakushijin and Tomonori Nakamura and Yoshiaki Kamei",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-34618-x",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline

T2 - A retrospective study

AU - Kawazoe, Hitoshi

AU - Uozumi, Ryuji

AU - Murakami, Akari

AU - Yamashita, Michiko

AU - Kobayashi-Taguchi, Kana

AU - Kusakabe, Erina

AU - Yamasawa, Haruna

AU - Yakushijin, Yoshihiro

AU - Nakamura, Tomonori

AU - Kamei, Yoshiaki

PY - 2018/12/1

Y1 - 2018/12/1

N2 - This study aimed to compare the antiemetic efficacy and safety of a four-drug combination with those of a standard three-drug combination in Japanese patients with breast cancer treated with anthracycline. We retrospectively analyzed data from Japanese patients with breast cancer, who had received their first cycle of anthracycline and were treated with aprepitant, palonosetron, and dexamethasone with or without olanzapine. This retrospective observational study was performed at Ehime University Hospital using the electronic medical records. Multivariable and propensity score-adjusted analyses were performed to compare the onset of complete response (CR) failure between the groups. One-hundred and thirty patients were included in this study and the four- and three-drug group had 22 and 108 patients, respectively. Similar to multivariable logistic regression analysis, propensity-adjusted logistic regression analysis revealed that the four-drug group was markedly associated with a decreased odds of CR failure in the overall, acute, and delayed phases (odds ratio [OR]: 0.27, 95% confidence interval [CI]: 0.10–0.73; OR: 0.28, 95% CI: 0.10–0.76; and OR: 0.15, 95% CI: 0.04–0.57, respectively). Additionally, treatment-related adverse events were well tolerated in both the groups. These findings suggest that the antiemetic efficacy of the four-drug combination is superior to that of the standard three-drug combination.

AB - This study aimed to compare the antiemetic efficacy and safety of a four-drug combination with those of a standard three-drug combination in Japanese patients with breast cancer treated with anthracycline. We retrospectively analyzed data from Japanese patients with breast cancer, who had received their first cycle of anthracycline and were treated with aprepitant, palonosetron, and dexamethasone with or without olanzapine. This retrospective observational study was performed at Ehime University Hospital using the electronic medical records. Multivariable and propensity score-adjusted analyses were performed to compare the onset of complete response (CR) failure between the groups. One-hundred and thirty patients were included in this study and the four- and three-drug group had 22 and 108 patients, respectively. Similar to multivariable logistic regression analysis, propensity-adjusted logistic regression analysis revealed that the four-drug group was markedly associated with a decreased odds of CR failure in the overall, acute, and delayed phases (odds ratio [OR]: 0.27, 95% confidence interval [CI]: 0.10–0.73; OR: 0.28, 95% CI: 0.10–0.76; and OR: 0.15, 95% CI: 0.04–0.57, respectively). Additionally, treatment-related adverse events were well tolerated in both the groups. These findings suggest that the antiemetic efficacy of the four-drug combination is superior to that of the standard three-drug combination.

UR - http://www.scopus.com/inward/record.url?scp=85056024512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056024512&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-34618-x

DO - 10.1038/s41598-018-34618-x

M3 - Article

C2 - 30389996

AN - SCOPUS:85056024512

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16232

ER -